Cardiac muscle repair or regeneration using bone marrow-derived stem cells
View Patent ↗Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
1. A method of improving left ventricular ejection fraction in a patient comprising the step of: administering to the patient adult allogeneic bone marrow-derived stem cells in an amount effective to improve ventricular ejection fraction.
2. The method of claim 1 , wherein the adult allogeneic bone marrow-derived stem cells are administered intravenously or intraarterially.
3. The method of claim 1 , wherein the adult allogeneic bone marrow-derived stem cells are administered in a pharmaceutically acceptable liquid carrier.
4. The method of claim 3 , wherein the pharmaceutically acceptable carrier comprises an isotonic liquid.
5. The method of claim 4 , wherein the isotonic liquid comprises phosphate buffer saline, physiological saline, culture medium, or 5% dextrose in water.
6. The method of claim 5 , wherein the isotonic liquid is physiological saline.
7. The method of claim 1 , wherein the adult allogeneic bone marrow-derived stem cells are administered in a suspension containing about 10×10 6 to about 40×10 6 adult allogeneic bone marrow-derived stem cells per ml.
8. A method of augmenting ventricular function in a patient comprising the step of: administering to the heart of the patient in need thereof a cell suspension, wherein the cell suspension comprises adult allogeneic bone marrow-derived stem cells and a pharmaceutically acceptable liquid medium, in an effective amount to augment ventricular function.
9. The method of claim 8 , wherein the patient has a left ventricular ejection fraction of less than about 40%.
10. The method of claim 8 , wherein the adult allogeneic bone marrow-derived stem cells are administered in a pharmaceutically acceptable liquid carrier.
11. The method of claim 10 , wherein the pharmaceutically acceptable carrier comprises an isotonic liquid.
12. The method of claim 8 , wherein the adult allogeneic bone marrow-derived stem cells are administered in a suspension containing about 10×10 6 to about 40×10 6 adult allogeneic bone marrow-derived stem cells per ml.